slides · global inventory
Rags To Riches
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 7,263
Current window 3,691-3,720
Pages 243
Rows per page 30
Arc
3,691-3,720 of 7,263
13
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate proof of concept.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
14
Includes two waterfall plots comparing patient responses; source cited as Novartis materials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Cost Of Inaction1 hit
16
Waterfall plot shows individual patient responses; table compares efficacy metrics against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
17
The slide uses a before-after-framing approach to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
18
The slide uses a swimmer plot to visualize individual patient treatment duration and response status.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
19
The slide uses a summary calculation (13/39 = 33.3% ORR) to aggregate results across two different clinical phases.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
20
Swimmer plot showing individual patient treatment duration and response status (NE, PD, PR, SD).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
21
The diagram uses a flow-chart structure to categorize patient outcomes (off treatment vs on treatment) and further breaks down the 'on treatment' group into SDs and PRs with specific progression delay metrics.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
22
The chart displays adverse events occurring in >=10% of patients (n=15).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
23
CoC = Cost of Care (or standard of care context); FIH = First-in-Human; PTS = Probability of Technical Success; CDP = Clinical Development Plan.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
25
The diagram shows the RAS/MAPK signaling pathway. The table provides a breakdown of patient populations for specific indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
26
The slide uses two tables to demonstrate competitive advantage in potency and pharmacokinetics.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
27
The diagram shows the signaling pathway with specific drug targets highlighted.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
28
The slide compares tumor volume reduction across two different CDX models (WiDr and RKO) using various treatment regimens.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
29
Includes waterfall plot and swimmer plot for clinical trial results.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
30
Data cut 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
31
The slide uses a process-oriented flow to demonstrate clinical validation milestones.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
32
The slide highlights selectivity and potency, using arrows to indicate performance relative to the competitor.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
33
Data presented as tumor volume over time (days) with error bars representing SEM.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
34
Includes RECIST 1.1 criteria reference and specific patient history.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
35
The table compares 'ALL' vs 'Gr >= 3' adverse events for different dosing regimens.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
36
The diagram shows the EGFR signaling pathway and the inhibitory effect of ERAS-801.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to contrast clinical outcomes across different indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
39
The chart is a Kaplan-Meier survival plot. The comparison shows ERAS-801 (blue line) outperforming standard EGFR inhibitors (Erlotinib, Lapatinib, Osimertinib) and vehicle control.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
40
The slide displays four distinct survival plots (HK301, GS025, HK336, GS187) showing statistically significant survival improvements (***) with ERAS-801 treatment.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
41
The slide uses a waterfall plot to show individual model responses and pie charts to summarize efficacy across the total cohort vs. the specific EGFR-mutant/amplified subset.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
42
The slide uses a table format to communicate a product roadmap for clinical development.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit